参考文献/References:
[1].Caforio AL,Pankuweit S,Arbustini E,et al. Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J,2013,34(33):2636-2648.
[2].Leone O,Pieroni M,Rapezzi C,et al. The spectrum of myocarditis:from pathology to the clinics[J]. Virchows Arch,2019,475(3):279-301.
[3].Matsuura H,Ichida F,Saji T,et al. Clinical features of acute and fulminant myocarditis in children—2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery[J]. Circ J,2016,80(11):2362-2368.
[4].Fung G,Luo H,Qiu Y,et al. Myocarditis[J]. Circ Res,2016,118(3):496-514.
[5].Sagar S,Liu PP,Cooper LT Jr . Myocarditis[J]. Lancet,2012,379(9817):738-747.
[6].Dominguez F,Kuhl U,Pieske B,et al. Update on myocarditis and inflammatory cardiomyopathy:reemergence of endomyocardial biopsy[J]. Rev Esp Cardiol (Engl Ed),2016,69(2):178-187.
[7].Bowles NE,Ni J,Kearney DL,et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults[J]. J Am Coll Cardiol,2003,42(3):466-472.
[8].Pankuweit S,Klingel K. Viral myocarditis:from experimental models to molecular diagnosis in patients[J]. Heart Fail Rev,2013,18(6):683-702.
[9].Lieberman EB,Hutchins GM,Herskowitz A,et al. Clinicopathologic description of myocarditis[J]. J Am Coll Cardiol,1991,18(7):1617-1626.
[10].中华医学会心血管病学分会精准医学学组,中华心血管病杂志编辑委员会,成人暴发性心肌炎工作组. 成人暴发性心肌炎诊断与治疗中国专家共识[J]. 中华心血管病杂志,2017,45(9):742-752.
[11].Felker GM,Boehmer JP,Hruban RH,et al. Echocardiographic findings in fulminant and acute myocarditis[J]. J Am Coll Cardiol,2000,36(1):227-232.
[12].McCarthy RE,Boehmer JP,Hruban RH,et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis[J]. N Engl J Med,2000,342(10):690-695.
[13].Ammirati E,Veronese G,Brambatti M,et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction[J]. J Am Coll Cardiol,2019,74(3):299-311.
[14].Kociol RD,Cooper LT,Fang JC,et al. Recognition and initial management of fulminant myocarditis:a scientific statement from the American Heart Association[J]. Circulation,2020,141(6):e69-e92.
[15].Billingham ME. Is acute cardiac rejection a model of myocarditis in humans[J]？ Eur Heart J,1987,8(Suppl J):19-23.
[16].Johnson DB,Balko JM,Compton ML,et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med,2016,375(18):1749-1755.
[17].Gallegos C,Rottmann D,Nguyen VQ,et al. Myocarditis with checkpoint inhibitor immunotherapy:case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate[J]. Eur Heart J Case Rep,2019,3(1):yty149.
[18].Litovsky SH,Burke AP,Virmani R. Giant cell myocarditis :an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells[J]. Mod Pathol,1996,9(12):1126-1134.
[19].Cooper LT Jr . Acute heart failure due to fulminant and giant cell myocarditis[J]. Herz,2006,31(8):767-770.
[20].Cooper LT Jr, Berry GJ,Shabetai R. Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators[J]. N Engl J Med,1997,336(26):1860-1866.
[21].Al Ali AM,Straatman LP,Allard MF,et al. Eosinophilic myocarditis:case series and review of literature[J]. Can J Cardiol,2006,22(14):1233-1237.
[22].Yusuf SW,Sharma J,Durand JB,et al. Endocarditis and myocarditis:a brief review[J]. Expert Rev Cardiovasc Ther,2012,10(9):1153-1164.
[23].Francis R,Lewis C. Myocardial biopsy:techniques and indications[J]. Heart,2018,104(11):950-958.
[24].Caforio ALP,Adler Y,Agostini C,et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease[J]. Eur Heart J,2017,38(35):2649-2662.
[25].Veronese G,Ammirati E,Cipriani M,et al. Fulminant myocarditis:Characteristics,treatment,and outcomes[J]. Anatol J Cardiol,2018,19(4):279-286.
[26].Brambatti M,Matassini MV,Adler ED,et al. Eosinophilic myocarditis:characteristics,treatment,and outcomes[J]. J Am Coll Cardiol,2017,70(19):2363-2375.
[27].Blauwet LA,Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis[J]. Heart Fail Rev,2013,18(6):733-746.
[28].Luyt CE,Hekimian G,Ginsberg F. Whats new in myocarditis[J]? Intensive Care Med,2016,42(6):1055-1057.
[29].Heymans S,Eriksson U,Lehtonen J,et al. The Quest for new approaches in myocarditis and inflammatory cardiomyopathy[J]. J Am Coll Cardiol,2016,68(21):2348-2364.
[30].Reiff C,Missov E. A Case of fulminant lymphocytic myocarditis responsive to immunosuppression[J]. Am J Med,2018131(11):e465-e466.
[31].Jurcova I,Rocek J,Bracamonte-Baran W,et al. Complete recovery of fulminant cytotoxic CD8 T-cell-mediated myocarditis after ECMELLA unloading and immunosuppression[J]. ESC Heart Fail,20207(4):1976-1981.
[32].Caforio ALP,Cheng C,Perazzolo Marra M,et al. How to improve therapy in myocarditis:role of cardiovascular magnetic resonance and of endomyocardial biopsy[J]. Eur Heart J Suppl,2019,21(Suppl B):B19-B22.
[33].Ammirati E,Cipriani M,Lilliu M,et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis[J]. Circulation,2017,136(6):529-545.
[34].Chen HS,Wang W,Wu SN,et al. Corticosteroids for viral myocarditis[J]. Cochrane Database Syst Rev,2013,10(10):CD004471.
[35].Andrea F,Russo MA,Cristina C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy:the TIMIC study[J]. Eur Heart J,2009,30(16):1995-2002.
[36].Merken J,Hazebroek M,van Paassen P,et al. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy[J]. Circ Heart Fail,2018,11(2):e004228.
[37].Wang S,Wei X,Hu H. STAR evidence evaluation of viral fulminant myocarditis:Specificity,Timeliness,Accessibility,Risk[J]. Eur Heart J,2020,41(34):3281-3282.
相似文献/References:
[1]孙文静,孙林,赵新湘.心脏核磁共振在急性心肌炎中的研究进展[J].心血管病学进展,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
SUN Wenjing,SUN Lin,ZHAO Xinxiang.Evolution of Cardiac Magnetic Resonance Imaging in Acute Myocarditis[J].Advances in Cardiovascular Diseases,2015,(4):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
[2]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(4):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[3]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(4):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[4]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(4):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[5]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(4):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(4):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[7]朱煜欣 王天博 刘晓翰 张悦 何韵 黄刚 徐俊波.炎症性心肌病的机制及治疗进展[J].心血管病学进展,2024,(4):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
ZHU Yuxin,WANG Tianbo,LIU Xiaohan,et al.Advances in the Pathogenesis and Treatment of Inflammatory Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(4):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
[8]陈文浩 张焕基 郭攸胜 张东辉.活检证实病毒性心肌炎的治疗策略及预后[J].心血管病学进展,2019,(5):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
Chen WenhaoZhang HuanjiGuo YoushengZhang Donghui.Treatment Strategy and Prognosis of Viral Myocarditis Confirmed by Biopsy[J].Advances in Cardiovascular Diseases,2019,(4):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]